Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine

Highlights • V503-006 was a randomized safety and immunogenicity study in females 12–26 years of age. • V503-006 evaluated 9vHPV vaccine in those with previous qHPV vaccination. • 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients. • 9vHPV vaccine was immunogenic for HPV 31/...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-11, Vol.33 (48), p.6855-6864
Hauptverfasser:	Garland, Suzanne M, Cheung, Tak-Hong, McNeill, Shelly, Petersen, Lone Kjeld, Romaguera, Josefina, Vazquez-Narvaez, Jorge, Bautista, Oliver, Shields, Christine, Vuocolo, Scott, Luxembourg, Alain
Format:	Artikel
Sprache:	eng
Schlagworte:	9-Valent Adolescent Adult Allergy and Immunology Antibodies, Viral - blood Cervical cancer Child Double-Blind Method Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Females GARDASIL HPV Human papillomavirus Humans Immunization Immunoassay Immunogenicity Injection Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Papillomavirus Vaccines - adverse effects Papillomavirus Vaccines - immunology Placebos - administration & dosage Safety Treatment Outcome Vaccine Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • V503-006 was a randomized safety and immunogenicity study in females 12–26 years of age. • V503-006 evaluated 9vHPV vaccine in those with previous qHPV vaccination. • 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients. • 9vHPV vaccine was immunogenic for HPV 31/33/45/52/58 in prior qHPV vaccine recipients.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.08.059